Literature DB >> 26193460

A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index.

Fumihito Hirai1, Toshiyuki Matsui2.   

Abstract

Various endoscopic indices (EIs) are available for evaluating the endoscopic features of ulcerative colitis (UC), but those currently used in clinical trials are not uniform and have been reported to vary considerably. The currently available EIs for UC include qualitative indices (Baron, Matts and Blackstone scores), the Rachmilewitz endoscopic index (REI; total sum of scores of four types of severity of mucosal lesions), among others. As each of these indices has its own unique characteristics, the selection of the proper EI has to be taken into account in the design of the clinical trial. Endoscopy is an observer-dependent diagnostic method, and inter-observer and intra-observer variations are often problematic. Among other factors, the reliability of clinical trials might be reduced considerably if inter-observer agreement is too low. To date, however, few analyses have focused on inter-observer variation in EIs for UC. The study reported here was undertaken to analyze inter-observer variations in the Baron score and REI. The κ statistics, an indicator of inter-observer agreement, was fair and not particularly high for either the Baron score (κ = 0.31) or REI (κ = 0.27). Modifications made to the REI (modified into a 4-point scale by the authors of this study), making it similar to the Baron score, resulted in κ statistics of 0.44 (moderate). The REI, designed to evaluate many mucosal abnormalities, seemed to enhance the validity of endoscopic grading of UC. It is desirable that inter-observer variations in various EIs are analyzed properly and reviewed comparatively. We emphasize the necessity of establishing the optimal EI for designing clinical trials of UC.

Entities:  

Keywords:  Clinical trials; Endoscopic indices; Inter-observer variation; Ulcerative colitis

Year:  2008        PMID: 26193460     DOI: 10.1007/s12328-008-0018-z

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  22 in total

1.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

Authors:  Brian G Feagan; Gordon R Greenberg; Gary Wild; Richard N Fedorak; Pierre Paré; John W D McDonald; Rejean Dubé; Albert Cohen; A Hillary Steinhart; Steven Landau; Rasha A Aguzzi; Irving H Fox; Margaret K Vandervoort
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

2.  Impact of observer variability on the usefulness of endoscopic images for the documentation of upper gastrointestinal endoscopy.

Authors:  Anne Mette Asfeldt; Bjørn Straume; Eyvind J Paulssen
Journal:  Scand J Gastroenterol       Date:  2007-09       Impact factor: 2.423

3.  The value of rectal biopsy in the diagnosis of ulcerative colitis.

Authors:  S G MATTS
Journal:  Q J Med       Date:  1961-10

4.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.

Authors:  A B Hawthorne; R F Logan; C J Hawkey; P N Foster; A T Axon; E T Swarbrick; B B Scott; J E Lennard-Jones
Journal:  BMJ       Date:  1992-07-04

5.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Authors:  D Rachmilewitz
Journal:  BMJ       Date:  1989-01-14

6.  Magnification endoscopy for diagnosis of nonerosive reflux disease: a proposal of diagnostic criteria and critical analysis of observer variability.

Authors:  A Edebo; W Tam; M Bruno; A-M Van Berkel; C Jönson; M Schoeman; G Tytgat; J Dent; L Lundell
Journal:  Endoscopy       Date:  2007-01-19       Impact factor: 10.093

7.  Intraobserver and interobserver consistency for grading esophagitis with narrow-band imaging.

Authors:  Yi-Chia Lee; Jaw-Town Lin; Han-Mo Chiu; Wei-Chih Liao; Chien-Chuan Chen; Chia-Hung Tu; Chi-Ming Tai; Tsung-Hsien Chiang; Yueh-Hsia Chiu; Ming-Shiang Wu; Hsiu-Po Wang
Journal:  Gastrointest Endosc       Date:  2007-08       Impact factor: 9.427

8.  Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.

Authors:  S A Riley; V Mani; M J Goodman; M E Herd; S Dutt; L A Turnberg
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

9.  Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

Authors:  R D Pullan; S Ganesh; V Mani; J Morris; B K Evans; G T Williams; J Rhodes
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

10.  Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis.

Authors:  Thomas de Lange; Stig Larsen; Lars Aabakken
Journal:  BMC Gastroenterol       Date:  2004-05-18       Impact factor: 3.067

View more
  3 in total

1.  Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.

Authors:  Yoichiro Iboshi; Kazuhiko Nakamura; Keita Fukaura; Tsutomu Iwasa; Haruei Ogino; Yorinobu Sumida; Eikichi Ihara; Hirotada Akiho; Naohiko Harada; Makoto Nakamuta
Journal:  J Gastroenterol       Date:  2016-05-13       Impact factor: 7.527

2.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hidetaka Sasaki; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

3.  Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.